218 related articles for article (PubMed ID: 15834643)
1. Severe delayed heart failure in three multiple sclerosis patients previously treated with mitoxantrone.
Goffette S; van Pesch V; Vanoverschelde JL; Morandini E; Sindic CJ
J Neurol; 2005 Oct; 252(10):1217-22. PubMed ID: 15834643
[TBL] [Abstract][Full Text] [Related]
2. Mitoxantrone-induced cardiotoxicity in patients with multiple sclerosis.
Hamzehloo A; Etemadifar M
Arch Iran Med; 2006 Apr; 9(2):111-4. PubMed ID: 16649351
[TBL] [Abstract][Full Text] [Related]
3. Results from the 5-year, phase IV RENEW (Registry to Evaluate Novantrone Effects in Worsening Multiple Sclerosis) study.
Rivera VM; Jeffery DR; Weinstock-Guttman B; Bock D; Dangond F
BMC Neurol; 2013 Jul; 13():80. PubMed ID: 23841877
[TBL] [Abstract][Full Text] [Related]
4. Long-term safety profile of mitoxantrone in a French cohort of 802 multiple sclerosis patients: a 5-year prospective study.
Le Page E; Leray E; Edan G;
Mult Scler; 2011 Jul; 17(7):867-75. PubMed ID: 21325016
[TBL] [Abstract][Full Text] [Related]
5. [Mitoxantrone].
Pericot I; Montalban X
Neurologia; 2003; 18(6):318-23. PubMed ID: 12838451
[TBL] [Abstract][Full Text] [Related]
6. Mitoxantrone in progressive multiple sclerosis: when and how to treat?
Gonsette RE
J Neurol Sci; 2003 Feb; 206(2):203-8. PubMed ID: 12559512
[TBL] [Abstract][Full Text] [Related]
7. [Acute heart failure in a patient treated by mitoxantrone for multiple sclerosis].
Feuillet L; Guedj E; Eusebio A; Malikova I; Pelletier J; Mundler O; Ali Chérif A;
Rev Neurol (Paris); 2003 Dec; 159(12):1169-72. PubMed ID: 14978418
[TBL] [Abstract][Full Text] [Related]
8. Mitoxantrone therapy in rapidly worsening multiple sclerosis.
Benesova Y; Stourac P; Beranek M; Kadanka Z
Bratisl Lek Listy; 2005; 106(3):141-3. PubMed ID: 16026151
[TBL] [Abstract][Full Text] [Related]
9. Mitoxantrone in relapsing-remitting and rapidly progressive multiple sclerosis: Ten-year clinical outcomes post-treatment with mitoxantrone.
Foo EC; Russell M; Lily O; Ford HL
Mult Scler Relat Disord; 2020 Sep; 44():102330. PubMed ID: 32599468
[TBL] [Abstract][Full Text] [Related]
10. Sequential maintenance treatment with glatiramer acetate after mitoxantrone is safe and can limit exposure to immunosuppression in very active, relapsing remitting multiple sclerosis.
Ramtahal J; Jacob A; Das K; Boggild M
J Neurol; 2006 Sep; 253(9):1160-4. PubMed ID: 16990994
[TBL] [Abstract][Full Text] [Related]
11. Management of worsening multiple sclerosis with mitoxantrone: a review.
Fox EJ
Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
[TBL] [Abstract][Full Text] [Related]
12. Predictive parameters of mitoxantrone effectiveness in the treatment of multiple sclerosis.
Debouverie M; Vandenberghe N; Morrissey SP; Anxionnat R; Pittion-Vouyovitch S; Vespignani H; Edan G
Mult Scler; 2004 Aug; 10(4):407-12. PubMed ID: 15327038
[TBL] [Abstract][Full Text] [Related]
13. Cardiac effects of mitoxanthrone therapy in patients with multiple sclerosis.
Pastuszak Ż; Tomczykiewicz K; Piusińska-Macoch R; Stępień A
Kardiol Pol; 2016; 74(4):380-4. PubMed ID: 26412472
[TBL] [Abstract][Full Text] [Related]
14. Suppression of mitoxantrone cardiotoxicity in multiple sclerosis patients by dexrazoxane.
Bernitsas E; Wei W; Mikol DD
Ann Neurol; 2006 Jan; 59(1):206-9. PubMed ID: 16374818
[TBL] [Abstract][Full Text] [Related]
15. Intravenous mitoxantrone and cyclophosphamide as second-line therapy in multiple sclerosis: an open-label comparative study of efficacy and safety.
Zipoli V; Portaccio E; Hakiki B; Siracusa G; Sorbi S; Amato MP
J Neurol Sci; 2008 Mar; 266(1-2):25-30. PubMed ID: 17870094
[TBL] [Abstract][Full Text] [Related]
16. Revision of the risk of secondary leukaemia after mitoxantrone in multiple sclerosis populations is required.
Pascual AM; Téllez N; Boscá I; Mallada J; Belenguer A; Abellán I; Sempere AP; Fernández P; Magraner MJ; Coret F; Sanz MA; Montalbán X; Casanova B
Mult Scler; 2009 Nov; 15(11):1303-10. PubMed ID: 19825889
[TBL] [Abstract][Full Text] [Related]
17. Ten-year follow-up after mitoxantrone induction for early highly active relapsing-remitting multiple sclerosis: An observational study of 100 consecutive patients.
Lefort M; Le Corre G; Le Page E; Rizzato C; Le Port D; Michel L; Kerbrat A; Leray E; Edan G
Rev Neurol (Paris); 2022 Jun; 178(6):569-579. PubMed ID: 35181157
[TBL] [Abstract][Full Text] [Related]
18. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial.
Hartung HP; Gonsette R; König N; Kwiecinski H; Guseo A; Morrissey SP; Krapf H; Zwingers T;
Lancet; 2002 Dec 21-28; 360(9350):2018-25. PubMed ID: 12504397
[TBL] [Abstract][Full Text] [Related]
19. The N-terminal pro-brain natriuretic peptide as a marker of mitoxantrone-induced cardiotoxicity in multiple sclerosis patients.
Podlecka-Piętowska A; Kochanowski J; Zakrzewska-Pniewska B; Opolski G; Kwieciński H; Kamińska AM
Neurol Neurochir Pol; 2014; 48(2):111-5. PubMed ID: 24821636
[TBL] [Abstract][Full Text] [Related]
20. [Aggressive multiple sclerosis. Definition and specific therapeutic indication].
Edan G
Presse Med; 2004 Feb; 33(3):187-91; discussion 192. PubMed ID: 15029034
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
